What's Happening?
Summit Therapeutics and its China-based partner Akeso are navigating the complexities of gaining FDA approval for their PD-1/VEGF-targeting antibody, ivonescimab. This drug has shown promising results in China, outperforming Merck's Keytruda in a Phase
3 trial for non-small cell lung cancer (NSCLC). However, the FDA's rejection of Eli Lilly's sintilimab, which was based solely on Chinese trial data, highlights the challenges faced by companies relying on single-country data. The FDA has recommended multiregional trials to ensure efficacy across diverse populations, a requirement that Summit and Akeso are addressing with their ongoing HARMONi-3 trial.
Why It's Important?
The FDA's cautious approach to approving drugs based on single-country data underscores the importance of demonstrating efficacy across diverse populations. This has significant implications for biopharma companies that conduct trials primarily in China, where the clinical trial landscape is rapidly expanding. The need for multiregional trials increases the time and cost of drug development, potentially delaying access to innovative treatments. For U.S. patients, this means that promising therapies developed abroad may take longer to become available, impacting treatment options for diseases like cancer.
What's Next?
Summit and Akeso are awaiting results from their multiregional HARMONi-3 trial, which could provide the necessary data to support FDA approval. The trial's outcome will be crucial in determining whether ivonescimab can be marketed in the U.S. Meanwhile, the FDA's decision on the drug is expected by November 14. The broader biopharma industry will be closely watching these developments, as they could set a precedent for how drugs developed in China are evaluated and approved in the U.S.
Beyond the Headlines
The FDA's stance on single-country data reflects broader concerns about the variability in clinical trial results across different populations. Factors such as genetic differences, socioeconomic status, and post-trial care can all influence outcomes. This highlights the need for a more nuanced approach to drug approval that considers these variables. Additionally, the growing role of China in global drug development raises questions about the balance between innovation and regulatory rigor, as well as the potential for international collaboration in clinical research.
